中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝硬化合并门静脉血栓治疗进展

李晓珂 杨新乐 王彤 薛舒文 郭晓林 季慧范

李晓珂, 杨新乐, 王彤, 等. 肝硬化合并门静脉血栓治疗进展[J]. 临床肝胆病杂志, 2021, 37(7): 1690-1693. DOI: 10.3969/j.issn.1001-5256.2021.07.045
引用本文: 李晓珂, 杨新乐, 王彤, 等. 肝硬化合并门静脉血栓治疗进展[J]. 临床肝胆病杂志, 2021, 37(7): 1690-1693. DOI: 10.3969/j.issn.1001-5256.2021.07.045
LI XK, YANG XL, WANG T, et al. Advances in the treatment of liver cirrhosis with portal vein thrombosis[J]. J Clin Hepatol, 2021, 37(7): 1690-1693. DOI: 10.3969/j.issn.1001-5256.2021.07.045
Citation: LI XK, YANG XL, WANG T, et al. Advances in the treatment of liver cirrhosis with portal vein thrombosis[J]. J Clin Hepatol, 2021, 37(7): 1690-1693. DOI: 10.3969/j.issn.1001-5256.2021.07.045

肝硬化合并门静脉血栓治疗进展

DOI: 10.3969/j.issn.1001-5256.2021.07.045
详细信息
    通讯作者:

    季慧范,jihf@jlu.edu.cn

  • 中图分类号: R575.2

Advances in the treatment of liver cirrhosis with portal vein thrombosis

  • 摘要: 门静脉血栓(PVT)是肝硬化的常见并发症之一,由于肝硬化存在凝血功能障碍和出血风险,临床上对于肝硬化合并PVT的治疗存在诸多争议。PVT常用治疗方法包括抗凝、介入和溶栓,重点阐述了肝硬化合并PVT的治疗现状,以期为临床制订规范合理的治疗策略提供帮助。

     

  • [1] NORONHA FERREIRA C, MARINHO RT, CORTEZ-PINTO H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver Int, 2019, 39(8): 1459-1467. DOI: 10.1111/liv.14121.
    [2] NICOARǍ-FARCǍU O, SOY G, MAGAZ M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis[J]. Semin Thromb Hemost, 2020, 46(6): 673-681. DOI: 10.1055/s-0040-1715473.
    [3] FACCIA M, AINORA ME, PONZIANI FR, et al. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate[J]. World J Gastroenterol, 2019, 25(31): 4437-4451. DOI: 10.3748/wjg.v25.i31.4437.
    [4] NERY F, CHEVRET S, CONDAT B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667. DOI: 10.1002/hep.27546.
    [5] VIOLI F, CORAZZA GR, CALDWELL SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian venous thrombotic events registry[J]. Intern Emerg Med, 2016, 11(8): 1059-1066. DOI: 10.1007/s11739-016-1416-8.
    [6] STINE JG, NORTHUP PG. Management of non-tumoral portal vein thrombosis in patients with cirrhosis[J]. Dig Dis Sci, 2019, 64(3): 619-626. DOI: 10.1007/s10620-018-5427-3.
    [7] COOL J, ROSENBLATT R, KUMAR S, et al. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort[J]. J Gastroenterol Hepatol, 2019, 34(6): 1088-1092. DOI: 10.1111/jgh.14501.
    [8] Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.

    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
    [9] QI X, SU C, REN W, et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 683-691. DOI: 10.1016/j.clinre.2015.02.012.
    [10] STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
    [11] MARUYAMA H, OKUGAWA H, TAKAHASHI M, et al. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574. DOI: 10.1038/ajg.2012.452.
    [12] LYU Y, HAN GH, FAN DM. progress of cirrhosis with portal vein thrombosis[J]. Chin J Dig, 2017, 37(8): 568-570. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.015.

    吕勇, 韩国宏, 樊代明. 肝硬化门静脉血栓研究进展[J]. 中华消化杂志, 2017, 37(8): 568-570. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.015.
    [13] European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
    [14] LIU PY, ZHOU Q, LIU CY, et al. The controversy and challenge of anticoagulation therapy for portal vein thrombosis in cirrhosis[J]. Chin J Intern Med, 2018, 57(7): 532-534. DOI: 10.3760/cma.j.issn.0578-1426.2018.07.015.

    刘培焱, 周琦, 刘春燕, 等. 肝硬化门静脉血栓抗凝治疗及其争议与挑战[J]. 中华内科杂志, 2018, 57(7): 532-534. DOI: 10.3760/cma.j.issn.0578-1426.2018.07.015.
    [15] MOHAN BP, ARAVAMUDAN VM, KHAN SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis[J]. Ann Gastroenterol, 2020, 33(5): 521-527. DOI: 10.20524/aog.2020.0503.
    [16] SCHEINER B, STAMMET PR, POKORNY S, et al. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function[J]. Wien Klin Wochenschr, 2018, 130(13-14): 446-455. DOI: 10.1007/s00508-018-1351-y.
    [17] CERINI F, VILASECA M, LAFOZ E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J]. J Hepatol, 2016, 64(4): 834-842. DOI: 10.1016/j.jhep.2015.12.003.
    [18] NORONHA FERREIRA C, REIS D, CORTEZ-PINTO H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J]. Dig Dis Sci, 2019, 64(9): 2671-2683. DOI: 10.1007/s10620-019-05572-z.
    [19] AHMED Z, SINGAL AK, KAMATH PS. Anticoagulants and their monitoring[J]. Clin Liver Dis (Hoboken), 2020, 16(4): 146-148. DOI: 10.1002/cld.946.
    [20] TURCO L, de RAUCOURT E, VALLA DC, et al. Anticoagulation in the cirrhotic patient[J]. JHEP Rep, 2019, 1(3): 227-239. DOI: 10.1016/j.jhepr.2019.02.006.
    [21] LIU JX, LI WT, ZHANG ZZ, et al. progress on pharmacological mechanism of LMWH and its clinical indications[J]. J Pharm Res, 2015, 34(7): 420-421, 424. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201507017.htm

    刘晋仙, 李玮涛, 张在忠, 等. 低分子肝素药理学机制及适应证研究进展[J]. 药学研究, 2015, 34(7): 420-421, 424. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201507017.htm
    [22] VILLA E, CAMMÀ C, MARIETTA M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J]. Gastroenterology, 2012, 143(5): 1253-1260. DOI: 10.1053/j.gastro.2012.07.018.
    [23] CUI SB, SHU RH, YAN SP, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol, 2015, 27(8): 914-919. DOI: 10.1097/MEG.0000000000000351.
    [24] ZHOU T, SUN X, ZHOU T, et al. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: A randomized controlled trial[J]. Clin Transl Gastroenterol, 2020, 11(9): e00228. DOI: 10.14309/ctg.0000000000000228.
    [25] AI MH, DONG WG, TAN XP, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2020, 32(10): 1395-1400. DOI: 10.1097/MEG.0000000000001846.
    [26] RODRIGUEZ-CASTRO KI, VITALE A, FADIN M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 34-42. DOI: 10.1097/MEG.0000000000001237.
    [27] The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.

    中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
    [28] DAVIS J, OGURICK AG, ROTHERMEL CE, et al. Anticoagulation and transjugular intrahepatic portosystemic shunting for treatment of portal vein thrombosis in cirrhosis: A systematic review and meta-analysis[J]. Clin Appl Thromb Hemost, 2019, 25: 1076029619888026. DOI: 10.1177/1076029619888026.
    [29] CAI GP, HUA ZH, XU P, et al. TIPS access to portal vein thrombolysis[J]. Chin J Gen Surg, 2019, 34(4): 336-339. DOI: 10.3760/cma.j.issn.1007-631X.2019.04.013.

    蔡高坡, 化召辉, 徐鹏, 等. 经TIPS途径治疗门静脉系统血栓[J]. 中华普通外科杂志, 2019, 34(4): 336-339. DOI: 10.3760/cma.j.issn.1007-631X.2019.04.013.
    [30] VALENTIN N, KORRAPATI P, CONSTANTINO J, et al. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30(10): 1187-1193. DOI: 10.1097/MEG.0000000000001219.
    [31] MEROLA J, FORTUNE BE, DENG Y, et al. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2018, 30(6): 668-675. DOI: 10.1097/MEG.0000000000001097.
    [32] LUCA A, MIRAGLIA R, CARUSO S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J]. Gut, 2011, 60(6): 846-852. DOI: 10.1136/gut.2010.228023.
    [33] WANG ZC, GU EL, WANG SP, et al. The treatment progress of cirrhosis with portal vein thrombosis[J]. Mod J Integr Tradit Chin West Med, 2016, 25(22): 2502-2505. DOI: 10.3969/j.issn.1008-8849.2016.22.

    王忠成, 顾尔莉, 王世蓬, 等.肝硬化门静脉血栓症的治疗进展[J]. 现代中西医结合杂志, 2016, 25(22): 2502-2505. DOI: 10.3969/j.issn.1008-8849.2016.22.
    [34] LIU YJ. Prophylaxis and management of patients with portal vein thrombosis complicting liver cirrhosis[J]. J Prac Hepatol, 2019, 22(4): 605-608. DOI: 10.3969/j.issn.1672-5069.2019.04.039.

    刘彦君. 肝硬化并发门静脉血栓防治研究进展[J]. 实用肝脏病杂志, 2019, 22(4): 605-608. DOI: 10.3969/j.issn.1672-5069.2019.04.039.
    [35] de SANTIS A, MOSCATELLI R, CATALANO C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: A pilot study[J]. Dig Liver Dis, 2010, 42(6): 451-455. DOI: 10.1016/j.dld.2009.08.009.
  • 加载中
计量
  • 文章访问数:  120
  • HTML全文浏览量:  27
  • PDF下载量:  65
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-07
  • 修回日期:  2021-01-22
  • 刊出日期:  2021-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回